Dapagliflozin, peptide YY, and weight loss in heart failure with preserved ejection fraction

Eur Heart J. 2024 Oct 5;45(37):3889-3891. doi: 10.1093/eurheartj/ehae534.
No abstract available

Keywords: HFpEF; Haemodynamics; Incretins; Obesity; Peptide YY; Proteomics; SGLT2 inhibitors; Weight loss.

MeSH terms

  • Benzhydryl Compounds* / pharmacology
  • Benzhydryl Compounds* / therapeutic use
  • Glucosides* / pharmacology
  • Glucosides* / therapeutic use
  • Heart Failure* / drug therapy
  • Heart Failure* / physiopathology
  • Humans
  • Peptide YY* / metabolism
  • Sodium-Glucose Transporter 2 Inhibitors* / pharmacology
  • Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use
  • Stroke Volume* / drug effects
  • Stroke Volume* / physiology
  • Weight Loss* / drug effects

Substances

  • dapagliflozin
  • Benzhydryl Compounds
  • Glucosides
  • Sodium-Glucose Transporter 2 Inhibitors
  • Peptide YY